Norgine Limited - search results

Ireland - English - HPRA (Health Products Regulatory Authority)

moviprep orange, powder for oral solution

norgine b.v. - macrogol 3350; sodium sulfate anhydrous; sodium chloride; potassium chloride; ascorbic acid; sodium ascorbate - powder for oral solution - . - osmotically acting laxatives; macrogol, combinations

Malta - English - Medicines Authority

moviprep, powder for oral solution

norgine bv antonio vivaldistraat 150, 1083 hp amsterdam, netherlands - macrogol, sodium sulfate, anhydrous, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate - powder for oral solution - sodium ascorbate 5.900 g sodium chloride 2.691 g ascorbic acid 4.700 g sodium sulfate anhydrous 7.500 g macrogol 3350 100 g potassium chloride 1.015 g - drugs for constipation

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

moviprep

norgine limited - sachet a-macrogol (macrogol 3350), sodium sulfate, sodium chloride, potassium chloride; sachet b-ascorbic acid, sodium ascorbate - powder for oral solution - sachet a-100g+7.5g+2.691g+1.015g

moviprep powder for oral solution

Australia - English - Department of Health (Therapeutic Goods Administration)

xifaxan rifaximin 200 mg film-coated tablet blister pack

norgine pty ltd - rifaximin, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; glyceryl isostearate; sodium starch glycollate type a; colloidal anhydrous silica; purified talc; hypromellose; titanium dioxide; disodium edetate; propylene glycol; iron oxide red - xifaxan is indicated for the treatment of patients ( > = 12 years of age) with travellers? diarrhoea caused by non-invasive strains of escherichia coli (see ?precautions?, and ?clinical trials? ). travellers? diarrhoea describes a clinical picture predominantly observed in subjects travelling from developed to developing countries. it is most frequently caused by enterotoxigenic escherichia coli (etec), enteroaggregative e. coli (eaec) and other non-invasive pathogens.

Australia - English - Department of Health (Therapeutic Goods Administration)

moviprep orange powder for oral solution sachet

norgine pty ltd - sodium sulfate, quantity: 7.5 g; macrogol 3350, quantity: 100 g; potassium chloride, quantity: 1.015 g; ascorbic acid, quantity: 4.7 g; sodium ascorbate, quantity: 5.9 g; sodium chloride, quantity: 2.691 g - powder - excipient ingredients: acesulfame potassium; aspartame; flavour - for bowel cleansing prior to any clinical procedure requiring a clean bowel e.g. bowel endoscopy, lower gastrointestinal tract radiology or digestive tract surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

moviprep powder for oral solution sachet

norgine pty ltd - ascorbic acid, quantity: 4.7 g; sodium chloride, quantity: 2.691 g; sodium sulfate, quantity: 7.5 g; potassium chloride, quantity: 1.015 g; macrogol 3350, quantity: 100 g; sodium ascorbate, quantity: 5.9 g - powder - excipient ingredients: acesulfame potassium; aspartame; flavour - for bowel cleansing prior to any clinical procedure requiring a clean bowel e.g. bowel endoscopy, lower gastrointestinal tract radiology or digestive tract surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

xifaxan rifaximin 550 mg tablet blister pack

norgine pty ltd - rifaximin, quantity: 550 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; titanium dioxide; glyceryl diisostearate; purified talc; hypromellose; propylene glycol; disodium edetate; colloidal anhydrous silica; iron oxide red; sodium starch glycollate type a - prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sinthrome 1mg tablets

norgine pharmaceuticals ltd - acenocoumarol - oral tablet - 1mg